TECARTUS™ can only be administered at an Authorized Treatment Center (ATC)1

In ZUMA-2, TECARTUS was provided as a single-dose, one-time
infusion manufactured within a median of 15 days from leukapheresis
to product delivery, with a 96% manufacturing success rate1-4*

steps in TECARTUS™ treatment process steps in TECARTUS™ treatment process

Pinch to zoom

*In the ZUMA-2 trial, 3 patients did not receive TECARTUS due to manufacturing failure.1
A lymphodepleting chemotherapy regimen is administered on the 5th, 4th, and 3rd day before infusion of TECARTUS. After thawing, premedication is administered 30 minutes to 1 hr prior to infusion, then TECARTUS is infused into patient.1

AR=adverse reaction; ATC=Authorized Treatment Center; CAR=chimeric antigen receptor.

References: 1. TECARTUS™ (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2020. 2. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma – study protocol. N Engl J Med. 2020;1-47. 3. Data on file. Kite Pharma, Inc; 2020. 4. Jacobson CA, Farooq U, Ghobadi A. Axicabtagene ciloleucel, an anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: practical implications for the community oncologist. Oncologist. 2020;25(1):e138-e146.